Canadian approval for Thoratec Laboratories:
This article was originally published in Clinica
Executive Summary
Thoratec Laboratories has received Canadian approval for its TLC-II portable VAD driver. The device is used to power the Thoratec VAD system which pumps blood to the body in heart failure patients awaiting transplantation. Its small size and light weight means that patients are mobile and independent after they leave the intensive care unit. The Pleasanton, California-based company said it is the only portable cardiac assist device which is capable of treating patients by providing right, left or biventricular support. The company has submitted an investigational device exemption to begin US clinical trials of the device.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.